MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNGlobeNewsWire · 1 day ago
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsGlobeNewsWire · Oct 15, 2026
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Oct 9, 2026
Stock Picks From Seeking Alpha's September 2026 New AnalystsSeeking Alpha · Oct 7, 2026
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 9, 2026
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts AheadSeeking Alpha · Sep 9, 2026MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.08 | $0.31 | Beat |
| May 13, 2026 | -$0.57 | -$0.58 | Miss |
| Mar 9, 2026 | -$0.42 | -$0.22 | Beat |
| Nov 12, 2025 | -$0.48 | $0.27 | Beat |
| Aug 14, 2025 | -$0.59 | -$0.57 | Beat |
| May 13, 2025 | -$0.61 | -$0.65 | Miss |